Roche commences tender offer for outstanding Poseida shares at $9 per share

Roche (RHHBY) announced that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (PSTX) at a price of $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of November 25, 2024 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Blue Giant Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and Poseida. The tender offer period will expire at one minute following 11:59 p.m., New York City time on 7 January, 2025, unless the offer is extended. Roche has filed a tender offer statement on Schedule TO with the United States Securities and Exchange Commission. Blue Giant Acquisition Corp. is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer.